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The quantity of T-lymphocytes reaching the draining lymph nodes from tumors is likely
important to mount effective distant responses and for the establishment of long term
systemic memory. Looking into mechanisms behind lymphocyte egress, we directed
our attention to leukocyte adhesion mechanisms inside tumors. Here we demonstrate
that activated T-cells form intra-tumor aggregates in a LFA-1-ICAM-1-dependent fashion
in mouse models of melanoma and breast cancer. We also provide evidence of the
presence of T-cell clusters in primary human melanoma. Disruption of LFA-1-ICAM-1
interactions, and thereby T-cell clustering, enhances the arrival of activated CD8+
T-cells to tumor draining lymph nodes in both transplanted and spontaneous cancer
models. Interestingly, upon ICAM-1 blockade, the expression of the chemotactic
receptor CCR7 augments in tumor infiltrating lymphocytes and in in-vitro de-clustered
T cells, as well as their ability to transmigrate across lymphatic endothelial cells. We
propose that ICAM-1-mediated homotypic T-lymphocyte aggregation may serve as a
tumor-mediated immune retention mechanism entrapping activated CD8+ T cells in
the tumor microenvironment. Modulation of T-cell adhesion may be of use to improve
the transit of activated lymphocytes toward the lymph nodes and their subsequent
recirculation.
Keywords: draining lymph nodes, T-lymphocyte retention, homotypic cell-adhesion, ICAM-1, immune response,
cancer immunotherapy
INTRODUCTION
Failure of T cell infiltration into tumors or in their recirculation from the tumor niche to the
draining lymph nodes (LNs) are some of the factors behind lack of therapeutic effects in patients
treated with immunotherapy. To develop competent cytotoxic functions, CD8+ T lymphocytes
must be efficiently primed by professional antigen presenting cells in the LNs (1). For this
purpose, naïve CD8+ T cells constantly traffic through secondary lymphoid organs where they
systematically scan the surface of dendritic cells searching for specific antigens (2, 3). In fact,
T lymphocytes are the major leukocyte cell type in steady-state afferent lymph (4).
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Once they have been activated in the LNs, T cells travel
to tumor affected tissues following chemokine gradients to
eradicate malignancy. Accordingly, patients with a pre-existing
immune infiltrate are better responders to check-point blockade
immunotherapy (5). For cold tumors, improved T-lymphocyte
entrance can be achieved by induction of chemokines such as
CXCL10, CCL2, or CCL5, that recruit T cells (6), by blood
vessel normalization or by depletion of suppressive immune
cells that hamper the entrance of tumor infiltrating lymphocytes
(TILs) (7).
However, T lymphocyte function goes beyond primary tumor
killing. Recent evidences show how antigen-experienced T cells
emigrate from tissues to secondary lymphoid organs following
chemotactic cues such as CCL21 or S1P (8–10). Memory CD4+
T lymphocytes and at much lower amounts CD8+ memory T
cells leave inflamed peripheral tissues through the lymphatic
vessels (LVs) (11). Although the molecular routes that regulate
T-cell egress from inflamed tissues have been extensively studied
it is far from clear whether the same mechanisms are at
work in leukocyte egress from tumors (12). Interestingly, recent
reports by Torcellan and co-workers demonstrated by in vivo
photolabeling of subcutaneous tumors, that tumor-egressing
T-cells constitute an heterogeneous population that includes
relatively high numbers of CD4+ and CD8+ T lymphocytes with
effector phenotypes and moderate amounts of IL-17 producing
CD4-CD8- double negative T lymphocytes (13). At this moment,
whether the lymph nodes constitute a transitory location for
effector lymphocytes traveling to distant metastases or a place for
further reactivation of memory T cells is an issue of research.
Different soluble and stroma-bound signals are responsible
of lymphocyte retention or egress from inflamed tissues. For
example, in the small intestine epithelium, brain and skin
epidermis, stromal TFGβ reduces the expression of T-bet by
resident memory T cells leading to activation of the integrin αE
(CD103) locus and T cell residence in the tissue by adhesion to
its ligand E-cadherin. In contrast, lamina propria memory T cells
that do not express CD103 depend on macrophages and antigen-
derived stimuli for lymphocyte retention (14). Lymphocyte
retention can also be accomplished by avoidance of exit cues
present in the stroma. Among them, inhibition of the egress
receptors sphingosine-1-phosphate receptor 1 (S1P1) (15) or
CCR7 (16).
In addition, tumors co-opt the adhesive mechanisms used
in inflamed tissues to regulate lymphocyte activation and
positioning within their stroma. In this sense, T-cell integrins
and their cognate ligands expressed on target cells, mainly
lymphocyte-function-associated antigen-1 (LFA-1)/intercellular
adhesion molecule-1 (ICAM-1) and CD103/E-cadherin play a
relevant role in the interactions between cytotoxic T lymphocytes
and tumor cells (17, 18). For instance, it has been reported in
breast tumor models how the reactivation of effector T cells
mostly depends on their binding to cognate antigen presented
Abbreviations: LFA-1, lymphocyte function-associated antigen 1; ICAM-1,
intercellular adhesion molecule 1; LNs, lymph nodes; LV, lymphatic vessels;
IMLEC, immortalized mouse lymphatic endothelial cells; mAb, monoclonal
antibody.
by tumor infiltrating CD103 expressing dendritic cells (19). In
addition, chemokines secreted by the inflamed stroma contribute
to homotypic and heterotypic intratumoral T cell adhesion, for
example regulating the avidity/affinity of key integrins such as
LFA-1 (20).
In this study, we explored the role played by the LFA-1 ligand
ICAM-1 in T cell retention in the tumor milieu. In a previous
work, we studied the intervention of the integrin ligands ICAM-1
or VCAM in leukocyte transmigration across the lymphatic
endothelium under inflammation (21). Moreover, the role of
ICAM-1/LFA-1 pairs in T cell crawling on initial lymphatics has
been recently addressed (22). However, nobody has investigated
yet the role played by ICAM-1 in tumor infiltrating lymphocytes’
exit from tumor.
To address this issue, we blocked ICAM-1 in mice that next
received intratumoral injections of activated T-lymphocytes. To
our surprise, we observed significant increases in the transit of
CD8+ T cells to the lymph nodes in LFA-1/ICAM-1 blocked
animals. The same increments were observed in a spontaneous
model of breast cancer. In all these cases, ICAM-1 blockade led to
in vitro and in vivo decrease of T-cell aggregates or clusters, with a
parallel increment in oriented cell migration and transmigration
across monolayers of lymphatic endothelial cells.
Therefore, since LFA-1/ICAM-1T cell aggregation seems
to limit T-cell recirculation, transient local blockade of these
functions offers opportunity to attain systemic bio-distribution
of tumor-reactive T-lymphocytes. Although, lack of data makes
debatable whether T-cell egress from tumors is a meaningful
phenomenon in cancer immunology (23), our results suggest
that modulation of LFA-1/ICAM-1 to implement T-lymphocyte
egress from malignant tissue is a possibility.
MATERIALS AND METHODS
Mice and Cell Lines
C57BL/6 female mice (6–7 weeks old) were obtained from
Harlan Laboratories and kept in our institutional animal facility
following ethical guidelines. OT1, OT1 CD45.1, and Her2/Neu
transgenic mice were bred in our laboratory. All procedures were
carried out in compliance with European Union and University
of Navarra (Institutional Animal Care and Use Committee
Protocol n◦ 168-12) relevant guidelines for the use of laboratory
animals.
Immortalized mouse lymphatic endothelial cells (IMLEC)
were cultured at 33◦C on collagen (Corning Life Sciences,
Corning, NY) and fibronectin (Millipore, Billerica, MA) coated
dishes (both 10µg/ml). Murine interferon-γ (IFNγ; 10 U/ml,
R&D Systems, Abingdon, UK) was added to induce the
expression of the large T-antigen during the expansion period.
IMLEC culture media was 40% DMEM, 40% F12-Ham, 20%
FBS (all from Gibco, Carlsbad, CA), 56µg/ml heparin (Sigma
Aldrich, St. Louis, MO), 10µg/ml endothelial cell mitogen
(AbD Serotec, Düsseldorf, Germany) and antibiotic antimycotic
solution (Life Technologies, Madrid, Spain). Lymphatic vessels
identity was confirmed by staining with antibodies against CD31
(BD Bioscience, Madrid, Spain), podoplanin and LYVE-1 (both
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formAbcam, Cambridge, UK). Before each experiment IFNγwas
removed from the cell growth media for at least 72 h.
B16-F10-OVA melanoma cells, which express the OVA257
epitope, and B16-F10-VEGFC cells (kindly donated by Dr.
Melody Swartz, Lausanne, Switzerland), which express the
vascular endothelial growth factor C, were cultured in complete
media containing RPMI 1640 medium (Gibco) supplemented
with 10% FBS, 100 U/ml penicillin/streptomycin (Gibco) and 5
× 10−5 M 2-mercaptoethanol (Gibco).
B16-F10-VEGFC-OVA cells were obtained by transfection
using lipofectamine 2000 (Thermo Fisher Scientific, Waltham,
MA). Twenty-four hours before transfection, 105 B16-VEGFC
cells were seeded in 6 well plates in 2ml complete media to
reach 70% confluence on the day of transfection. Cells were
then transfected with a plasmid containing OVA, and 72 h after
transfection, selection with geneticin 1 mg/ml was started and
maintained for 1 week. Expression of OVA and VEGFC by
stably transfected cells was checked by flow cytometry using
FACSCanto (BD Bioscience).
In vitro CD8+ T-Lymphocyte Activation
Naïve OT1T cells (enriched from spleens of OT1 CD45.1
C57BL/6 mice) were activated by exposure to 100 ng/ml OVA.
For clustering assays, 30min prior to activation, 10µg/ml anti-
ICAM-1 mAb (clone YN1/1.7.4), anti-LFA-1 mAb (clone M17/4)
or IgG2b kappa monoclonal isotype control (clone RTK4530;
all from Biolegend, San Diego, CA) were added to the cell
culture. Brightfield images of cell clusters were acquired 24
and 48 h after activation using an inverted microscope (Leica,
Wetzlar, Germany). Image quantification was performed using
ImageJ software. For de-clustering assays, OT1 lymphocytes
which had been activated for 48 h were transferred to 96-well
plates and treated with 10µg/ml anti-ICAM-1, anti-LFA-1 or
isotype control. Images were acquired 24 h after the addition of
the mAbs and quantification was performed using ImageJ.
CD8+ T-lymphocytes from spleens of Balb/c mice were
isolated using the CD8α T Cell Isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) and following manufacturer’s
instructions. Cells were further activated with plate-bound anti-
CD3ε (0.5µg/ml; clone 145-2C11; Biolegend) and anti-CD28
(1µg/ml; clone 37.51; Biolegend) in complete culturemedia. Two
days later, CD8+ T cells were labeled with violet proliferation dye
450 (BD Bioscience) before being injected into the tumors.
Migration Assays
For transmigration assays, 4 × 104 IMLEC were seeded on
the top membrane of transwell Boyden chambers with a 5-
µm pore size (Corning Life Sciences) pre-coated with type I
rat tail collagen (Becton Dickinson, Franklin Lakes, NY). Cells
were allowed to attach overnight at 37◦C. One day later, TNF-α
(Peprotech, London, UK) was added onto confluent endothelial
cell monolayers at a final concentration of 100 ng/ml. Cells were
maintained in culture for extra 12 and 1 h before the addition of
lymphocytes, anti-ICAM-1 or anti-LFA-1 antibodies were added
at a concentration of 10µg/ml. Activated OT1 CD8+ T cells
were first stained with deep red CellTracker (Thermo Fisher
Scientific) and then exposed or not to blocking antibodies at the
same concentration and time as IMLEC monolayers. Then, 105
OT1 cells were added onto the IMLEC monolayer in the upper
well of the transwell inserts. Cells were allowed to transmigrate
for 12 h at 37◦C. Migrated cells were collected from the lower
compartment and quantified using a Neubauer chamber. Images
of the remaining cells in the upper well of the Boyden chamber
were acquired by confocal microscopy and quantified using
Image J software.
To test lymphocyte 3D migration, OT1 T-lymphocytes were
activated by 48 h-exposure to OVA in the presence of 10µg/ml
anti-ICAM-1 mAb or in the presence of a kappa monoclonal
isotype control. Cells were stained with a CellTracker CMRA
orange (Thermo Fisher Scientific) and embedded in 3D collagen
matrices (PureCol EZ Gel solution, Sigma Aldrich). Lymphocyte
movement toward CCL21 (SLC) gradients was recorded by in
vivo confocal microscopy using LSM 800 with Airyscan (Zeiss,
Jena, Germany). The cell directionality ratio is defined as the
straight-line length between the starting point and the endpoint
of the migration trajectory, divided by the total length of the
trajectory. This ratio is equal to 1 for a straight cell trajectory and
approaches 0 for a highly curved trajectory (24). It was analyzed
using IMARIS software (Bitplane, Belfast, UK).
Flow Cytometry
OT1 T-lymphocytes activated for 48 h in the presence or absence
of ICAM-1 blocking mAbs were stained with antibodies against
the chemokine receptors CCR7 (clone 4B12; Biolegend). Single
cell suspensions from tumors and lymph nodes were stained
with antibodies against CD45.1 (clone A20, Biolegend) and
counted using perfect count beads (Cytognos, Salamanca, Spain)
as internal standards. Dead cells were excluded using the Zombie
NIR Fixable viability kit (Biolegend). Cells were collected with
FACSCanto II and cell acquisition data was analyzed using
FlowJo software (Treestar, Ashland, OR).
Confocal Microscopy
For immunofluorescence-based analysis, samples were frozen,
cut into 5µm slices and stained overnight with 1:100 dilutions
in TBS 1X of rabbit anti-mouse LYVE-1, rat anti-mouse CD8
(clone 53–6.7, Biolegend), PE anti-mouse CD45.1 (clone A20,
Biolegend) or 488 anti-mouse CD11b (clone M1/70, Biolegend)
antibodies. Isotype specific secondary antibodies conjugated to
Alexa-Fluor 488, 594 or 647 (Life Technologies) were used
as needed. Cell nuclei were stained with Hoechst 33258 (Life
Technologies) and imaged on a LSM 800 confocal microscope
(Zeiss) equipped with a 63X Apochromat (N/A= 1.4).
Image quantification was performed using ImageJ and LSM
image analyzer software (Zeiss). For CD8+ T cell analysis,
a region of interest (ROI) was determined manually. Mean
fluorescence intensity (MFI) of CD8+ signal on each ROI
was analyzed using ImageJ. CD8+ T cell clusters and CD8+
and CD11b co-staining was manually delimited and quantified
using ImageJ. Aggregates of four or more cells were considered
clusters.
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Immunohistochemistry
Formalin-fixed, paraffin-embedded melanoma tissue sections
were obtained from remnant samples collected for clinically-
indicated procedures after firmed consent. Endogenous
peroxidase activity was quenched with hydrogen peroxide,
and antigen retrieval was carried out in citrate buffer pH 6.
Nonspecific binding was blocked using 5% normal goat serum
in TBS for 30min. Sections were incubated with anti-CD8a
antibody (clone HPA037756, Atlas Antibodies, Bromma,
Sweden) overnight at 4◦C. Afterwards, samples were incubated
with Envision polymer (Dako, Glostrup, Denmark) for 30min at
room temperature.
In vivo Studies
For in vivo migration experiments, C57BL/6 mice or Her2/Neu
transgenic mice were used. C57BL/6 mice were injected
subcutaneously with 5 × 105 B16-VEGFC cells in both flanks.
When tumors reached sizes of about 7 × 7mm, tumors were
inflamed by an intratumoral injection of 20 ng/ml of TNF-
α. Two days later mice were treated intraperitoneally (i.p.)
with anti-ICAM-1 (50 µg per mouse), anti–LFA-1 (100 µg per
mouse) blocking mAbs or rat IgG2b isotype control (50 µg per
mouse). Eight hours later C57BL/6 and Her2/Neu mice where
adoptively transferred with 0.5 × 105 activated OT1 CD45.1
cells or 0.3 × 105 activated CD8+ T cells respectively. When
indicated, mice were intravenously injected with 3 µg pertussis
toxin (PTx) 4 h after mAb treatment (Sigma-Aldrich). Two days
later, mice were humanly sacrificed and T-lymphocytes were
recovered from tumors and draining lymph nodes. For this
purpose, isolated tumors were incubated with Collagenase-D and
DNase-I (Roche, Madrid, Spain) for 15min at 37◦C, followed by
mechanical disaggregation and filtration in a 70-µm cell strainer
(BD Bioscience). Tumor infiltrating lymphocytes were isolated
from stromal cells through Percoll gradients. Lymph nodes were
mechanically disaggregated and filtrated through a 70-µm cell
strainer in order to obtain a single-cell suspension.
For in vivo migration experiments with naïve OT1 cells,
C57BL/6 mice were injected subcutaneously with 5×105 B16-
VEGFC-OVA cells in both flanks. When tumors reached sizes
of about 7 × 7mm, tumors were inflamed with an intratumoral
injection of 20 ng/ml of TNF-α. Forty-eight hours later, mice
were adoptively transferred with intravenous injections of
5·106 naïve OT1 lymphocytes. Two days later, mice were
treated intraperitoneally with anti-ICAM-1 (50 µg per mouse)
or rat IgG2b isotype control (50 µg per mouse) and daily
intraperitoneal injections of 5 mg/kg FTY720 (fingolimod,
Sigma). Two days later, mice were humanly sacrificed and T-
lymphocytes were recovered from tumors and draining lymph
nodes.
Statistical Analyses
Statistical analyses were performed using SPSS 17.0 software
(SPSS, Chicago, IL, USA). Normal distribution was assured
by use of the Kolmogorov–Smirnov test. If the distribution
was normal, the significance was calculated with t-test or
ANOVA (Shapiro–Wilk), if not, the significance was estimated by
nonparametric tests such as Mann–Whitney U-test. In all cases,
one (∗), two (∗∗), or three (∗∗∗) asterisks indicate significances of
p < 0.05, p < 0.01, and p < 0.001, respectively.
RESULTS
ICAM-1 Blockade Increments the
Migration Rates of Intratumorally
Administered T-Lymphocytes to the
Draining Lymph Nodes
Our main objective was to study whether ICAM-1 played a
role in the egress of antigen experienced T cells from tumors
to the lymph nodes. To study this issue, we administered
intratumorally OT1T cells that had been previously activated
in vitro by exposition to OVA antigen. Specifically, we injected
5 × 105 in vitro-activated OT1T cells intratumorally into
B16-VEGFC mouse melanoma tumors [with intense lymphatic
vascularization (25), Supplementary Figure 1A] that had been
pre-treated 8 h earlier with an ICAM-1 blocking antibody.
Two days later, mice were sacrificed and tumors and lymph
nodes were extracted and processed for T-cell detection by
immunofluorescence and flow cytometry. Contrarily to what
we expected, we observed significantly higher counts of
T-lymphocytes reaching the draining lymph nodes in mice
treated with an anti-ICAM-1 antibody than in isotype (IgG)
treated animals (Figure 1A). LFA-1 (αLβ2) is the integrin ligand
for ICAM-1. In order to prove that ICAM-1/LFA-1 interaction
was responsible of T cell retention, we performed the experiments
pre-blocking the β2 integrin LFA-1 instead. As occurred with
ICAM-1 blockade, this strategy resulted in incremented T
cell emigration from tumors toward draining lymph nodes
(Figure 1A). Accordingly, we also observed that the number
of adoptively transferred T cells remaining in tumors varied
accordingly, being higher in control than in ICAM-1 or LFA-1
treated mice (Figures 1B,C).
We then postulated that the incremented CD8+ T cell
retention was due to ICAM-1 mediated lymphocyte-tumor
interaction. To test this, we first detected by flow cytometry
the intensity of ICAM-1 expression on the surface of tumor
cells. As shown in Supplementary Figure 1B, B16-melanoma
cells express ICAM-1 on their surfaces at significantly lower (10-
fold less) levels than T cells, in accordance with what had already
been described (26). Moreover, when we analyzed the adhesion
of T cells to monolayers of B16-VEGFC melanoma cells, we
observed very weak adhesion that did not change regardless of
the assays being done in the presence of anti-ICAM-1 antibodies
(Supplementary Figure 1C). These results lead us to postulate
that ICAM-1 blockade may contribute to diminished T cell
retention in tumors by mechanisms different from direct T-cell
adhesion to tumor cells.
Next, to clarify whether our observations were exclusive
of the B16-VEGFC tumor model, we performed the ICAM-
1 blocking experiments in Her2/Neu transgenic mice bearing
spontaneous breast tumors. These tumors presented less intense
basal T cell infiltrates than B16-VEGFC tumors in spite
of possessing abundant intra- and peritumoral lymphatic
vasculature (Supplementary Figure 1D). In this case, we were
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FIGURE 1 | Systemic ICAM-1 blockade increases the egress of intratumorally injected CD8+ T-cells to draining LNs. (A) Percentages of total CD45.1+ CD8+ T cells
injected in B16-VEGFC tumors that reached the draining LNs 48 h after isotype (n = 29), anti-ICAM-1 (n = 32), or anti-LFA-1 (n = 12) treatment and detected by flow
cytometry. (B) Representative confocal images of B16-VEGFC tumors in mice treated with isotype, anti-ICAM-1 or anti-LFA-1 antibodies showing CD45.1+ T cells
(red) and intratumoral LVs (green). (C) Percentages of CD45.1+ CD8+ T-lymphocytes remaining in B16-VEGFC tumors 48 h after isotype, anti-ICAM-1 or anti-LFA-1
antibody treatment. Percentage of positive area was calculated using a manual region of interest (ROI) based on CD45.1 signal. At least 12 pictures from 3 different
tumors where analyzed in each case. (D) Percentages of total CD8+ T cells injected in Her2/Neu tumors that reached the draining LNs after isotype (n = 6) or
anti-ICAM-1 (n = 8) treatment and detected by flow cytometry. (E) Percentages of total CD8+ T cells injected in Her2/Neu tumors that remained in tumors 48 h after
isotype (n = 6) or anti-ICAM-1 (n = 8) treatment and detected by flow cytometry. (F) Percentages of CD8+ T-lymphocytes remaining in Her2/Neu tumors 48 h after
isotype or anti-ICAM-1 antibody treatment. Percentage of positive area was calculated using a manual region of interest (ROI) based on CD8 signal. At least 23
pictures from 3 different tumors where analyzed in each case (*p < 0.05, **p < 0.01, ***p < 0.001).
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able to induce higher migration of intratumorally-injected
CD8+ T-lymphocytes to draining lymph nodes in mice pre-
treated with ICAM-1 blocking mAbs (Figure 1D). In the
same sense, the amount of T-lymphocytes that remained in
the tumor tissue was significantly decreased in anti-ICAM-
1 treated mice (Figure 1E). We confirmed these results by
immunofluorescence-based inspection of the Her2/Neu tumors
with clear reductions in the number of CD8+ T-lymphocytes in
tumors derived from ICAM-1 pre-treated animals (Figure 1F).
These results confirmed that the effect observed was not
model-dependent.
ICAM-1 Blockade Increments the Egress of
in vivo Activated T Cells
Up to this moment, our experimental set up comprised the
intratumoral injection of high numbers of exogenously activated
OT1T cells. Next, we wanted to test whether our results were
reproducible in a more physiologic experimental context.
For that purpose, we introduced naïve OT1 CD8+ T cells
intravenously in mice harboring pre-inflamed subcutaneous
B16-VEGFC-OVA melanomas, which present intense lymphatic
vascularization and express OT-1 cognate antigen OVA
(Supplementary Figure 2A), allowing them to infiltrate tumors
for 48 h. At this time point, mice were treated i.p. with FTY720
(fingolimod) to block further T-cell egress from the lymph nodes
and half of the mice were treated with i.p. injections of ICAM-1
blocking antibodies. Two days later, mice were sacrificed and
the number CD8+ OT1T lymphocytes in tumors and lymph
nodes were quantified by flow cytometry. With this experimental
setting (Figure 2A) we assumed that the differences observed in
OT1T cell counts in the lymph nodes were mostly accountable to
cell egress from tumors and not to increased recirculation from
the lymph nodes. In fact, OT1 cell counts in peripheral blood
of fingolimod-treated animals were almost negligible 24 and
48 h after treatment with this drug (Supplementary Figure 2B).
In this new in vivo setting, ICAM-1 blockade was also able
to increment the amount of OT1T cells present in the lymph
nodes of treated animals and showed a tendency to minor (albeit
FIGURE 2 | In vivo activated T-cells experience increased migration from tumors to the LNs after ICAM-1 blockade. (A) Treatment schedule. (B) Percentages of
intravenously injected CD45.1+ CD8+ T cells in the draining LNs 48 h after treatment with isotype (n = 9) or anti-ICAM-1 (n = 6) antibodies of mice bearing
B16-VEGFC-OVA tumors. Cells were detected by flow cytometry. (C) Percentages of intravenously injected CD45.1+ CD8+ T cells that remained in
B16-VEGFC-OVA tumors 48 h after treatment with isotype (n = 9) or anti-ICAM-1 (n = 6) antibodies and detected by flow cytometry. (D) Mean fluorescence intensity
of CCR7 expression in CD45.1+ CD8+ T cells remaining in B16-VEGFC-OVA tumors in mice treated as in C. (*p < 0.05).
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not significant) incidence of OT1T cells remaining in tumors
(Figures 2B,C).
T-cell migration to the lymph nodes occurs through
chemokine mediated guidance being CCL21 (27) one of the
main chemokines responsible for their recruitment. We then
checked the expression of the chemokine receptor CCR7
that binds to the lymphatic attracting chemokine CCL21 in
tumor infiltrating OT1T cells. As depicted in Figure 2D, we
detected significant increments in the expression of CCR7 in
intratumoral OT1T cells from anti-ICAM-1 treated animals.
With these results we demonstrate how transient blockade
of ICAM-1 may improve intratumoral T cell migration to
the lymph nodes and favor the intra tumor expression
of one of the most important lymph node chemotactic
receptors.
Migration of ICAM-1 Blocked
T-Lymphocytes Is Dependent on GPCRs
Once we had sufficiently proved the reproducibility of the
effect of transient ICAM-1 blockade in CD8+ T cell egress
from tumors, we aimed at searching the cellular mechanism
behind it. Therefore, in the first place we determined the
expression of the chemokine receptor CCR7 in lymphocytes
activated in vitro in the presence or in the absence of anti-
ICAM-1 antibodies. As shown in Figure 3A, ICAM-1 blockade
was again associated with increments in the expression of
CCR7 on the surface of CD8+ T-lymphocytes. To find
out if these changes in CCR7 expression were responsible
for the improved cell migration, we measured in vitro cell
migration toward gradients of CCL21 in ICAM-1 blocked
or isotype (IgG) pre-treated OT1 cells. In these assays, we
observed significant increments in cell directionality toward
gradients of CCL21 (Figure 3B) in ICAM-1 pre-blocked
T-lymphocytes.
To provide an in vivo correlate for these findings, we again
injected CD8+ T-lymphocytes in B16-VEGFC tumors from
mice that had been or not pre-treated with anti-ICAM-1
antibodies but, in this case, half of the mice were pre-
treated with the G-protein inhibitor Pertussis Toxin 4 h
before OT1 transfer. This inhibitor precludes signaling
through chemokine receptors. Notably, inhibition of G-
protein signaling abrogated ICAM-1 induced increments
in T cell migration (Figure 3C). Moreover, when we
compared the expression of CCR7 in OT-1 lymphocytes
that had reached the lymph nodes from anti-ICAM-1 or IgG
treated mice, we did not find differences between groups
(Figure 3D). Hence, differential CCR7 expression after ICAM-1
blockade is transient and occurs in tumor stroma infiltrating
lymphocytes.
Therefore, our results demonstrate that inhibition of ICAM-1
augments chemokine-signaling conducive to T cell migration to
the lymph nodes.
FIGURE 3 | Integrin ligand blockade leads to increments in chemokine-dependent migration. (A) Surface expression of the chemokine receptor CCR7 on in vitro
activated OT-1 CD8+ T cells in the presence or in the absence of anti-ICAM-1 antibodies. Flow-cytometry data was collected from three or more independent
experiments. (B) Chemokine-directed migration of activated CD45.1+ CD8+ T lymphocytes in 3D collagen gels after being treated with anti-ICAM-1 antibodies or
control IgG for 48 h. Cell movement toward CCL21 gradients was recorded by in vivo confocal microscopy and cell straightness was analyzed using IMARIS software.
Each dot represents a single tracked cell. At least 80 cells were tracked in each case. (C) Percentages of intratumorally-injected CD45.1+ CD8+ T cells that reached
the draining LNs 48 h after treatment with isotype antibody (n = 35), isotype + PTx (n = 6), anti-ICAM-1 antibody (n = 39), or anti-ICAM-1 + PTx (n = 10). (D) Mean
fluorescence intensity of CCR7 expression in LN CD45.1+ CD8+ T cells 48 h after treatment with isotype (n = 26) or anti-ICAM-1 (n = 33) antibodies. Cells were
detected by flow cytometry (**p < 0.01, ***p < 0.001).
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Transient ICAM-1 Blockade Diminishes the
Occurrence of Intratumoral T Cell Clusters
Next, we wondered whether augmented T cell egress after
ICAM blockade was due to changes in the viability of
tumor infiltrating lymphocytes or alterations in lymphatic
vessels phenotype after treatment. To that aim, the viability
of exogenously administered CD8+ T lymphocytes was
analyzed by zombie nir staining, but we did not find
any increment in the amount of dead cells neither in
the tumor nor in the LNs of B16-VEGFC bearing mice
(Supplementary Figure 3A). When we checked PD-1 expression
of intratumorally injected CD45.1 CD8+ T lymphocytes we did
not find any difference either (Supplementary Figure 3B).
Besides, there were also no changes in the viability of
CD8+ T lymphocytes transferred to Her2/Neu tumors
(Supplementary Figure 3C).
Microscopic inspection of B16-VEGFC tumors showed no
morphological changes in intra- or peri-tumoral lymphatic
vessels in mice treated with ICAM-1 blocking antibodies
(Supplementary Figure 3D). However, it called our attention
to observe intratumoral T-cell clusters in control tumors
injected with activated CD8+ T cells that were significantly
decreased in anti-ICAM-1 treated mice (Figures 4A,B).
We also observed the same phenomenon when LFA-1 was
blocked (Figures 4C,D). T-cell clustering by LFA-1 integrin
mediated homotypic binding is a hallmark of T-lymphocyte
activation (28).
T cell clusters are usually associated with CD11b myeloid
cells (29). To inspect whether this was the case in the tumor
tissue, we searched for the presence of CD11b+ myeloid cells
in T cell clusters. As shown in Supplementary Figures 4A,B,
CD11b+ myeloid cells were present in the vicinity of such T
cell aggregates. In spite of not observing instances of T cells
rossetting around CD11b+ cells, we could detect frequent images
of side to side cell association. We were unable to detect
any colocalization with CD11b+ cells in anti-ICAM-1 treated
mice.
To rule out the possibility of a model specific effect,
we evaluated the presence of T cell clusters in spontaneous
breast tumors that arise in Her2/Neu transgenic mice also
following intratumoral injection of activated CD8+ T cells
(Figure 4E). Although at a much lower extent than in B16-
VEGFC tumors, in this model we also observed the formation
of T cell clusters. Importantly, we were unable to detect any
T cell clusters in spontaneous tumors from ICAM-1 pre-treated
animals (Figures 4E,F). Therefore, exposure to anti-ICAM-1
impedes the formation of leukocyte clusters inside the tumor
tissue.
Finally, we investigated whether T cell clusters actually exist in
pathological tissue specimens obtained from melanoma patients.
Immunohistochemistry studies of tissue sections revealed that
CD8+ T cell clusters are formed in human tumors and
therefore tumors may retain T-lymphocytes through homotypic
adhesive mechanisms, potentially susceptible of in situ ICAM-
1 blockade to enhance T cell egress to the lymph nodes
(Figure 4G).
ICAM-1 Blockade Favors T Cell
De-Clustering and Increments Migration
Across Monolayers of Lymphatic
Endothelial Cells
To further support the importance of ICAM-1-mediated T-cell
aggregation to impede migration, we performed in vitro CD8+
T cell clustering and de-clustering assays and subsequently
checked lymphocyte migration. First, we performed in vitro
CD8+ T-lymphocyte clustering assays in the presence of anti-
ICAM-1 or anti-LFA-1 antibodies following activation with an
OVA-derived peptide. ICAM-1 and LFA-1 blockade significantly
diminished T-cell aggregation (Figures 5A,B). When we checked
by flow cytometry the proliferation (CSFE dilution), activation
(CD25 staining), viability (7-AAD staining), and apoptosis
(caspase 3) we could not find any significant difference
between groups (Supplementary Figure 5), therefore ICAM-1
pre-treatment does not affect activation. In parallel experiments,
we studied whether the presence of ICAM-1 or LFA-1 blocking
antibodies were able to disaggregate the already formed T cell
clusters. Reversion of the aggregates took place as shown in
Figures 5C,D. We then evaluated the transmigration of clustered
CD8+ T cells across monolayers of lymphatic endothelial cells
in the presence or in the absence of ICAM-1/LFA-1 blocking
antibodies and verified significant increments in transmigration
when the assays were performed in the presence of anti-ICAM-
1 or anti-LFA-1 antibodies (Figure 5E). Not surprisingly, when
we checked the upper well of the Boyden chambers by confocal
microscopy we discovered large CD8+ T cell clusters in control
isotype treated cells (Figures 5F,G). From these results we suggest
that one mechanism behind ICAM-1 blockade incremented out-
migration from tumors might be disaggregating T cell clusters,
and thus facilitating single cell migration across the lymphatic
endothelium into the vessel lumen.
To sum up, transient ICAM-1 blockade significantly affects
the migratory properties of intratumoral leukocytes.
DISCUSSION
In this study we experimentally support a mechanism of T-cell
retention in tumors by LFA-1/ICAM-1 mediated leukocyte
aggregation. Such a mechanism seems to prevent CD8+ T cell
recirculation. The presence of T cells forming aggregates
in human tumors has been broadly described and their
composition vary from simple clusters of lymphocytes to more
complex structures reminiscent of secondary lymphoid organs
(30, 31).
In the present work, we demonstrate the presence of small
diffuse aggregates of T lymphocytes in human melanoma
tissue section and in animal models of melanoma and breast
carcinoma. In our experimental models, blockade of ICAM-
1 before intratumoral delivery of activated CD8+ T cells
resulted in decrements in intratumoral T-cell clusters and
in the amount of intratumoral CD8+ T-cells. Importantly,
these results were accompanied by augmented CD8+ T cell
arrival to draining lymph nodes. Blockade of LFA-1 in parallel
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FIGURE 4 | Intratumoral CD8+ T-cells form diffuse cell-clusters that are reduced upon anti-ICAM-1 treatment. (A) Representative confocal images of B16-VEGFC
tumors from isotype or anti-ICAM-1 treated mice showing CD45.1+ T cells (orange), CD8+ T cells (red), and intratumoral LVs (green). Images at the right end show
magnifications of T cell clusters. (B) Percentages of area occupied by CD45.1+ CD8+ T-lymphocyte clusters in B16-VEGFC tumors 48 h after isotype or anti-ICAM-1
antibody treatment. Percentage of total area occupied by T cell clusters was calculated using a manual quantification of aggregates of four or more cells. At least 13
pictures where analyzed in each case. (C) Representative confocal images of B16-VEGFC tumors from isotype or anti-LFA-1 treated mice showing CD45.1+ T cells
(orange) and CD8+ T cells (red). (D) Percentages of area occupied by CD45.1+ CD8+ T-lymphocyte clusters in B16-VEGFC tumors 48 h after isotype or anti-LFA-1
antibody treatment. Percentage of total area occupied by T cell clusters was calculated using a manual quantification of aggregates of four or more cells. At least 19
pictures where analyzed in each case. (E) Representative confocal images of Her2/Neu tumors in isotype or anti-ICAM-1 treated mice showing CD8+ T cells (red).
(F) Percentages of area occupied by CD8+ T-lymphocyte clusters in Her2/Neu tumors 48 h after isotype or anti-ICAM-1 antibody treatment. Percentage of total area
occupied by T cell clusters was calculated using a manual quantification of aggregates of four or more cells. At least 26 pictures where analyzed in each case.
(G) Representative microphotograph showing CD8+ T cell clusters as detected by immunohistochemistry on samples obtained from a series of 10 human melanoma
patients. Magnifications show two instances of T cell clusters (*p < 0.05, **p < 0.01, ***p < 0.001).
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FIGURE 5 | In vitro blockade of the ICAM-1/LFA-1 pair abolishes T cell clustering and speeds their transmigration across lymphatic monolayers. (A) Representative
microphotographs of CD45.1+ CD8+ T cell clusters after in vitro activation for 24 or 48 h in the presence of control isotype or anti-ICAM-1 or anti-LFA-1 antibodies.
(B) Quantification of T cell cluster formation in A calculated as the percentage of total area that is occupied by T-cell clusters. Pooled data from at least two
independent experiments are shown. (C) Representative microphotographs showing destruction of already-formed T cell clusters of CD45.1+ CD8+ activated
T lymphocytes being subsequently treated for 24 h with isotype control, anti-ICAM-1 or anti-LFA-1 antibodies. (D) Quantification of T cell clusters was performed as in
B. (E) Transmigration of activated CD45.1+ CD8+ T cells for 16 h across monolayers of IMLEC through serum-containing medium. The assays were performed in the
presence of anti-ICAM-1 or anti-LFA-1 antibodies or control IgG. Data from five independent experiments are shown. (F) Percentages of CD8+ T-lymphocytes
remaining in the upper well of Boyden chambers after transmigration assays as in E. Percentages of total area occupied by T-cell clusters was calculated using a
manual region of interest (ROI) based on CD8+ signal. At least nine pictures where analyzed in each case. (G) Representative confocal images of OT1 CD8+
lymphocytes (red) that remained in the upper well of transwell Boyden chambers after transmigration experiments as in E (*p < 0.05, **p < 0.01, ***p < 0.001).
experiments produced the same results as when animals were
treated with anti-ICAM-1 antibodies, proving that ICAM-1/LFA-
1 axis mediates the modulation of lymphocyte egress from
tumors. Furthermore, we observed the same effect when ICAM-1
was blocked 48 h after intravenous injection of naïve T-cells
recognizing tumor antigens.
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FIGURE 6 | ICAM-1-LFA-1 dependent CD8+ T-lymphocyte aggregation in tumor tissue prevents recirculation to draining lymph nodes. (A) Intra-tumoral CD8+ T
lymphocytes form clusters that are retained in the tumor microenvironment by homotypic ICAM-1-LFA-1 interactions. (B) ICAM-1 blockade results in destruction of
T-cell clusters and increased T cell sensitivity to CCL21 chemokine-guided migration toward the lymphatic vessels, thus facilitating their transit to the draining lymph
nodes.
T cell clustering or aggregation has been considered a
hallmark of in vitro and in vivo T-cell activation (32). In this
process, LFA-1/ICAM-1 adhesion facilitates T-cell activation
through their contribution to the immunological synapse (33). As
a result, T cell proliferation and differentiation are orchestrated
through the activation of signaling cascade events. For example,
adhesive contacts between T-cells and antigen presenting cells
serve to exchange cytokines which are important for T cell
activation, such as IFNγ and IL-2 (29, 34, 35). Although it was
established that T cells deficient in ICAM-1 exhibit phenotypes
of terminally differentiated cells (28), in our hands in vivo short-
term ICAM-1 blockade did not alter the expression of activation
markers such as the immune checkpoint inhibitor PD-1 neither
produced any difference in the viability of tumor infiltrating
leukocytes. In this context, it is interesting to bring in a recent
work published by R. Alon and co-workers in which the authors
demonstrate how ICAM-1/LFA-1 interactions are dispensable for
functional immune synapses between dendritic cells and CD4+
T cell in the lymph nodes (36).
In our view, de-construction of ICAM-1 mediated T cell
clusters leads to the release of single T cells to freely migrate
and enter the lymphatic vasculature. In fact, tumors are not the
only instance of ICAM-1-mediated T-cell retention. For example,
antigen-dependent intrahepatic CD8+ T cells are restrained
from emigration by LFA-1/ICAM-1 mediated mechanisms (37).
In this vein, LFA-1 is used by liver-resident T cells as a molecular
switching device to patrol the hepatic sinusoids being their
engagement dependent on stromal expression of ICAM-1 (38).
In search for a mechanism that may contribute to the
increased migration observed in anti-ICAM-1 treated animals,
we looked for differences in the expression of chemokine
receptors by intratumoral T cells after ICAM-1 blockade and
observed higher expression of the CCL21 receptor CCR7.
Increased expression of this chemokine receptor was consistent
with greater in vitro directional migration toward cognate
chemotactic cues. In this framework, it is known that lymphatic
endothelial cells produce CCL21 and how dendritic cell adhesion
to lymphatic vessels induces the release of CCL21 depots
by lymphatic endothelial cells that contribute to attract and
increment their transmigration (39). The mechanism of CCR7
upregulation after ICAM-1 blockade remains to be elucidated.
In accordance to the role of CCR7, in vivo treatment with
pertussis toxin returned T cell migration to the LNs to
baseline in ICAM-1 blocked animals. Interestingly, it has
been described that T cell migration through the interstitium
occurs independently of integrin-mediated interactions. In this
situation, T-lymphocytes spread rapidly and extend cytoplasm
protrusions on stroma-immobilized CCL21 (40). Our data
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supports this point because ICAM-1 blockade did not impair
lymphocyte access to the lymphatic vessels but on the contrary,
it was incremented. Therefore, our interpretation is that ICAM-
1 blockade results in destruction of T-cell clusters and increased
T cell sensitivity to CCL21 chemokine-guided migration toward
the lymphatic vessels, thus facilitating their transit to the lymph
nodes.
Recently, an in vivo-photolabeling based study described that
T lymphocyte egress from tumors is diverse and highly regulated
(13). In previous reports from our group and others it has
been described how ICAM-1 participates in leukocyte adhesion
and transmigration across the lymphatic vasculature (22, 41). In
fact, although in steady-state conditions lymphocytes cross the
endothelial layer through an integrin indolent process (42), under
inflammation or shear stress this process switches to integrin-
dependent modes (21, 43, 44). Moreover, this same integrin
ligand has been involved in intravascular lymphocyte crawling
inside initial lymphatic capillaries (22). In our experimental
model, since systemic ICAM-1 blockade did not prevent the
access of tumor egressing CD8+ T lymphocytes to the lymphatic
vessels, we assume that their transit is integrin independent
and would probably occur through small portals that due to
small size would not fit cell aggregates of more than 2-3
T-cells (42).
In summary, we propose that LFA-1/ICAM-1 mechanism is
not needed for T-lymphocyte transendothelial transit neither for
their advancement through the tumor stroma. By contrast, it is
used by intra-tumoral T cells to build up cell clusters that are
retained in the tumor microenvironment (Figure 6).
Our finding that blockade of ICAM-1 increments lymphocyte
migration to the lymph nodes opens important perspectives
for the treatment of cancer. In this sense, we envision a
treatment scenario in which ICAM-1 acts locally in combination
with adoptive T-cell therapy to increment the migration of
lymphocytes to the lymph nodes to establish a memory
population or to expand the immune response. In our view
and based on scientific grounds, the use of systemic anti-
ICAM-1 antibodies as a single agent may offer important
limitations. First, it is important to bear in mind that long term
interference with LFA-1/ICAM-1 interactions would disrupt
critical immune synapses and the entrance of leukocytes into the
tumor from the bloodstream (29). In fact, there are evidences
of incremented autoimmunity in mice with type 1 Diabetes
Mellitus treated with anti-ICAM-1 antibodies in combination
with IL-2 (45). Even more, some tumors cells express ICAM-
1 on their surface or start to express it after irradiation (46).
In these cases ICAM-1 is also an important target to induce
a specific T-cell response against tumors. This is in the basis
of using ICAM-1 sequences in the formulation of TRICOM
vaccines to treat prostate cancer (47). Moreover, CAR-T cells
targeting ICAM-1 are able to eliminate advanced human thyroid
tumors, which express increased ICAM-1 (48). Therefore, the
type of cancer to be treated with ICAM-1 blocking mAbs should
be carefully selected based on its expression of ICAM-1. In
our case, B16 mouse melanoma cells expressed significantly
dimmer ICAM-1 than leukocytes or endothelial cells, even under
inflammation.
Two recent clinical assays using BI-505, a fully human IgG1
monoclonal antibody directed against intercellular adhesion
molecule-1, have been reported. The first one entailed a Phase
I dose-escalation study in patients suffering from advance
relapsed/refractory multiple myeloma (49). The second assay
consisted in an open arm-phase 2 clinical trial enrolling four
patients diagnosed with smoldering multiple myeloma and
showed no relevant clinical activity although treatment was well
tolerated (50). Interestingly, a Phase I/II study of BI-505 in
conjunction with autologous stem cell transplant in multiple
myeloma (NCT02756728) was terminated due to and adverse
cardiopulmonary event in the clinical study (as reported in the
informative press note released by BioInvent in November 2016).
Currently, there are no evidences of any open assay using BI-505
or other anti-ICAM-1 mAb as single agent or in combination to
treat cancer.
In light of the abovementioned data, we assume that anti-
ICAM-1 mAbs may be more useful locally and in combination
therapies. Since immunotherapy activates the immune system,
and ICAM-1 blockade diminishes tumor retention and improves
lymphocyte recirculation, patients with metastasis, multiple or
recurrent lesions could benefit from this combination. In our
view, transient treatment with ICAM-1 blocking antibodies
together with immunotherapy would release cytotoxic T
lymphocytes caught up in clusters, setting them free to kill tumor
cells or egress to the dLNs and to subsequent lesions. In this
sense, more experiments are warranted to uncover the nature of
the lymphocyte subpopulations exiting the tumor and their effect
in the generation of memory responses. Timing, spatial location
and dosage of treatments with anti-ICAM-1 antibodies deserve
further research.
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